Gliflozin drugs are a class of medications that inhibit reabsorption of glucose in the kidneys and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2, and are therefore also called SGLT-2 inhibitors. These drugs include:
- Dapagliflozin (Farxiga)
- Dapagliflozin-metformin (Xigduo XR)
- Canagliflozin (Invokana)
- Canagliflozin-metformin (Invokamet)
- Empagliflozin (Jardiance)
- Empagliflozin-linagliptin (Glyxambi)
- Empagliflozin-metformin (Synjardy)
NOTE: Drugs in the class called SGLT-2 inhibitor increase your risk of developing diabetic ketoacidosis (DKA), a dangerous and potentially fatal condition. Mainstream medicine/healthcare providers seem largely unaware of this and that makes it even scarier. Several diabetics have already been hospitalized for DKA following the addition of SGLT2 meds; all survived, but we don’t want any more people put at risk. YOU may have to educate your healthcare provider on this – and by doing so, you will help others as well as yourself.
References:
SGLT-2 Inhibitors
https://lowcarbrn.wordpress.com/diabetes/drugs-to-treat-diabetes/sglt-2-inhibitors/
Invokana: Diabetes Drug Gets Black Box Warning for Amputation Risks
SGLT-2 drug
https://www.diabetesdaily.com/blog/invokana-diabetes-drug-gets-black-box-warning-for-amputation-risks-417024/
Classes of Medications
- Alpha-glucosidase inhibitors
- Biguanides (metformin)
- Dopamine agonist (Cycloset)
- DPP-4 inhibitors (gliptins) (Januvia, Onglyza)
- GLP-1 (glucagon-like peptides) (Trulicity, Victoza)
- Insulin
- Meglitinides
- Sodium glucose transporter (SGLT-2 Inhibitors) (Farxiga, Invokana, Jardiance)
- Sulfonylureas (glipizide, glyburide)
- Thiazolidinediones (Avandia, Actos)